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Simple Summary: Sarcopenia and non-alcoholic fatty liver disease share common pathological
and physiological mechanisms that can co-occur with aging. Low skeletal muscle mass index and
non-alcoholic fatty liver disease were related, regardless of abdominal obesity. Maintenance of muscle
mass should be emphasized for prevention of non-alcoholic fatty liver disease. Management of fatty
liver also could be an important strategy to preserve muscle mass.
Abstract: Although sarcopenia is known to be a risk factor for non-alcoholic fatty liver disease
(NAFLD), whether NAFLD is a risk factor for the development of sarcopenia is not clear. We
investigated relationships between NAFLD and low skeletal muscle mass index (LSMI) using three
different datasets. Participants were classified into LSMI and normal groups. LSMI was defined as a
body mass index (BMI)-adjusted appendicular skeletal muscle mass <0.789 in men and <0.512 in
women or as the sex-specific lowest quintile of BMI-adjusted total skeletal muscle mass. NAFLD was
determined according to NAFLD liver fat score or abdominal ultrasonography. The NAFLD groups
showed a higher hazard ratios (HRs) with 95% confidence intervals (CIs) for LSMI than the normal
groups (HRs = 1.21, 95% CIs = 1.05–1.40). The LSMI groups also showed a higher HRs with 95%
CIs for NAFLD than normal groups (HRs = 1.56, 95% CIs = 1.38–1.78). Participants with NAFLD
had consistently less skeletal muscle mass over 12 years of follow-up. In conclusion, LSMI and
NAFLD showed a relationship. Maintaining muscle mass should be emphasized in the management
of NAFLD.
Keywords: sarcopenia; non-alcoholic fatty liver disease; obesity; skeletal muscle mass; inflammation
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic
liver disease worldwide with increasing obesity, metabolic syndrome, and dyslipidemia [1]
affecting up to 20% in the general population [2,3] and 16–33% in Korean, respectively [4].
In addition, increased interest of the importance of NAFLD in recent years has led to
studies of various treatment modalities for NAFLD [5–7]. However, until now, there is
no firmly recommended medical treatment for NAFLD [5–7]. The mainstay of treatment
of NAFLD is still the adoption of lifestyle modifications including sustained weight loss,
increased physical activity, and maintaining the healthy weight [5–7].
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Aging is closely associated with increased accumulation of lipids in non-adipose
tissues and organs [8]. Liver is the key organ that is mainly affected by ectopic fat accumula-
tion [9]. Because the sarcopenia and NAFLD share common pathological and physiological
mechanisms, the co-occurrence of sarcopenia and NALFD has been observed in elderly [10].
Several epidemiologic studies have shown that sarcopenia was a risk factor for incident
NAFLD [11–14]. However, there were few studies to investigate whether NAFLD is a risk
factor or the consequential result for sarcopenia and to verify the relationship between
NAFLD and sarcopenia. If NAFLD is associated with the occurrence of sarcopenia, the
maintenance of muscle mass in NAFLD patients should be emphasized more strongly, as
patients with sarcopenia have an increased risk of all-cause mortality [15,16]. Therefore,
this study aimed to investigate the relationship between NAFLD and the skeletal muscle
mass using three Korean population-based datasets.
2. Results
2.1. General Characteristics of the Study Population
The clinical characteristics of the study population according to NAFLD status are
shown in Table 1. According to the analysis of study population, by classifying them into
normal and NAFLD groups, the proportions of male sex were significantly higher in the
NAFLD group than that in the normal group in all three datasets. The mean levels of
age, waist circumference (WC); body mass index (BMI); mean blood pressure (MBP); total
cholesterol, triglyceride, aspartate aminotransferase (AST); and alanine aminotransferase
(ALT) were significantly higher in the NAFLD group than those in the normal group.
The mean value of basal energy expenditure (BEE) and high-density lipoprotein (HDL)
cholesterol were significantly lower in the NAFLD group. Prevalence of abdominal obesity
and proportion of history of cardiovascular disease (CVD) were also higher in the NAFLD
group, whereas proportion of current smoker was higher in the NAFLD group. The
proportion of current drinker regular exercise was higher in the NAFLD group from
the Gangnam Severance Hospital Check-up (GSHC) dataset, whereas those were higher
in the NAFLD group from Korean National Health and Nutrition Examination Survey
(KNHANES) and Korean Genome and Epidemiology Study (KoGES) dataset. The NAFLD
group in the KoGES had significantly higher daily amount of total caloric intake, and
carbohydrate intake although the NAFLD group in the KNHANES did not show significant
differences in all nutrients intake. The mean value of skeletal muscle mass index (SMI)
was lower in the NAFLD groups in all dataset. The proportions of LSMI were significantly
higher in NAFLD group than normal group.
The clinical characteristics of the study population according to presence of low
skeletal muscle maa index (LSMI) are shown in Table 2. The mean levels of age, WC, BMI,
MBP, total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, AST, and
ALT were significantly higher in the LSMI group than those in the normal group from the
all datasets. The mean values of BEE, HDL cholesterol, daily caloric intake, protein intake,
and fat intake were lower in the LSMI group. The mean value of NAFLD-liver fat score
and prevalence of NAFLD were higher in the LSMI group in the KNHANES and KoGES.
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Table 1. Clinical characteristics of three different population cohorts according to non-alcoholic fatty liver disease (NAFLD) status.
2016–2019 Gangnam Severance Hospital Check-Up 2008–2010 KNHANES KoGES: Ansan-Ansung Study
Variables Normal NAFLD p * Normal NAFLD p † Normal NAFLD p *
N 5523 4168 6343 1977 3579 1008
Male sex, % 37.6 65.5 <0.001 37.9 49.6 <0.001 40.9 47.2 <0.001
Age, years 47.4 ± 13.1 51.2 ± 11.5 <0.001 47.3 ± 0.4 51.0 ± 0.6 <0.001 50.0 ± 8.3 52.3 ± 8.4 <0.001
Abdominal obesity, % 11.4 47.6 <0.001 17.5 45.3 <0.001 13.0 55.2 <0.001
Waist circumference, cm 76.7 ± 9.3 88.2 ± 9.6 <0.001 78.6 ± 0.2 87.0 ± 0.3 <0.001 78.7 ± 7.7 87.7 ± 7.6 <0.001
BMI, kg/m2 22.5 ± 3.0 26.1 ± 3.5 <0.001 22.9 ± 0.1 25.6 ± 0.1 <0.001 23.5 ± 2.6 26.0 ± 2.7 <0.001
Mean blood pressure, mmHg 86.6 ± 8.8 89.7 ± 9.2 <0.001 89.6 ± 0.3 94.5 ± 0.4 <0.001 89.8 ± 12.2 98.5 ± 11.7 <0.001
Basal energy expenditure, kcal/day 1340.9 ± 209.1 1484.2 ± 227.3 <0.001 1333.3 ± 3.5 1421.8 ± 7.6 <0.001 1356.4 ± 179.1 1452.4 ± 207.9 <0.001
Fasting glucose, mg/dL 94.5 ± 13.7 106.7 ± 25.9 <0.001 93.8 ± 0.3 109.0 ± 1.0 <0.001 82.5 ± 11.9 97.4 ± 32.3 <0.001
Fasting insulin, µIU/mL - - - 8.5 ± 0.1 14.1 ± 0.2 <0.001 6.5 ± 2.7 10.7 ± 7.7 <0.001
Total cholesterol, mg/dL 201.8 ± 36.3 208.3 ± 41.2 <0.001 185.6 ± 0.6 193.4 ± 1.2 <0.001 187.3 ± 33.6 201.0 ± 36.4 <0.001
Triglyceride, mg/dL 88 (67, 120) 141 (102, 197) <0.001 115.1 ± 1.4 172.6 ± 4.0 <0.001 115 (89, 151) 191 (150, 258) <0.001
HDL cholesterol, mg/dL 61.1 ± 13.3 51.6 ± 11.3 <0.001 49.3 ± 0.2 44.2 ± 0.3 <0.001 46.3 ± 9.9 39.6 ± 7.9 <0.001
LDL cholesterol, mg/dL 126.0 ± 29.6 135.7 ± 32.6 <0.001 113.4 ± 0.6 114.7 ± 1.1 0.306 115.1 ± 30.4 119.8 ± 33.0 <0.001
AST, IU/L 24 (20, 30) 27 (22, 35) <0.001 19.8 ± 0.1 29.9 ± 0.8 <0.001 25 (22, 29) 29 (24, 36) <0.001
ALT, IU/L 18 (13, 25) 29 (20, 41) <0.001 17.2 ± 0.1 36.2 ± 0.8 <0.001 20 (16, 26) 31 (24, 45) <0.001
Current smoker, % 13.3 22.7 <0.001 18.7 22.7 0.008 21.0 24.0 0.045
Current drinker, % 60.9 63.9 0.002 52.3 51.1 0.474 44.6 42.3 0.195
Regular exercise, % 23.8 25.6 0.043 23.6 20.4 0.028 52.1 49.8 0.193
Daily caloric intake, kcal/day - - - 1855.5 ± 14.9 1889.4 ± 27.4 0.225 1842.8 (1539.9, 2194.0) 1881.1 (1577.5, 2291.0) 0.003
Daily protein intake, g/day - - - 67.0 ± 0.8 68.8 ± 1.2 0.171 62.4 (48.4, 78.0) 63.9 (50.3, 79.8) 0.057
Daily fat intake, g/day - - - 36.4 ± 0.6 37.5 ± 1.2 0.323 29.9 (20.1, 41.1) 29.8 (19.7, 41.7) 0.579
Daily CHO intake, g/day - - - 308.2 ± 2.4 312.1 ± 4.2 0.380 322.7 (277.8, 375.1) 331.0 (288.1, 397.2) <0.001
Skeletal muscle index 1.866 ± 0.352 1.845 ± 0.356 0.005 0.751 ± 0.003 0.744 ± 0.006 0.308 1.828 ± 0.312 1.794 ± 0.305 0.002
NAFLD liver fat score - - - −1.819 ± 0.127 0.368 ± 0.036 <0.001 −1.951 ± 0.638 0.479 ± 1.606 <0.001
LSMI, % 11.8 30.9 <0.001 8.4 15.7 <0.001 - - -
History of CVD, % 4.4 5.7 0.002 3.0 5.2 0.001 2.1 3.3 0.046
Abbreviations: KNHANES, Korean National Health and Nutrition Examination Survey; KoGES, The Korean Genome and Epidemiology Study; NAFLD, non-alcoholic fatty liver disease; SE, standard error; BMI,
body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CHO, carbohydrate; LSMI, low skeletal muscle mass index; CVD,
cardiovascular disease. * p derived from Student’s t-test for continuous variables and chi-square test for categorical variables. † p derived from weighted generalized linear regression analysis for continuous
variables and weighted chi-square test for categorical variables.
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Table 2. Clinical characteristics of three different population cohorts according to skeletal muscle mass index (SMI) status.
2016–2019 Gangnam Severance
Hospital Check-Up 2008–2010 KNHANES KoGES: Ansan-Ansung Study
Variables Normal LSMI p * Normal LSMI p † Normal LSMI p *
N 7753 1938 7412 908 3405 831
Male sex, % 49.6 49.7 0.939 40.3 41.9 0.487 41.7 42.8 0.562
Age, years 47.5 ± 12.1 55.5 ± 12.3 <0.001 45.6 ± 0.4 62.0 ± 0.8 <0.001 49.9 ± 8.3 55.1 ± 8.8 <0.001
Abdominal obesity, % 19.3 57.9 <0.001 21.1 47.3 <0.001 12.2 30.3 <0.001
Waist circumference, cm 79.7 ± 10.2 89.4 ± 10.7 <0.001 79.7 ± 0.2 86.8 ± 0.6 <0.001 78.6 ± 7.6 83.8 ± 8.0 <0.001
BMI, kg/m2 23.2 ± 3.1 27.6 ± 3.9 <0.001 23.3 ± 0.1 25.8 ± 0.2 <0.001 23.4 ± 2.5 25.9 ± 3.0 <0.001
Mean blood pressure, mmHg 87.5 ± 8.9 90.0 ± 9.4 <0.001 90.1 ± 0.3 95.6 ± 0.6 <0.001 89.8 ± 12.2 94.1 ± 12.6 <0.001
Basal energy expenditure,
kcal/day 1413.7 ± 229.8 1357.8 ± 217.3 <0.001 1362.4 ± 3.7 1268.3 ± 7.4 <0.001 1359.2 ± 179.8 1314.1 ± 167.0 <0.001
Fasting glucose, mg/dL 97.9 ± 18.6 107.1 ± 26.7 <0.001 96.3 ± 0.3 105.2 ± 1.3 <0.001 82.4 ± 11.6 83.3 ± 12.7 0.057
Fasting insulin, µIU/mL - - - 9.6 ± 0.1 11.1 ± 0.3 <0.001 6.4 ± 2.7 6.5 ± 2.8 0.914
Total cholesterol, mg/dL 203.5 ± 37.8 208.9 ± 41.4 <0.001 186.4 ± 0.6 196.0 ± 1.8 <0.001 186.9 ± 33.7 195.9 ± 34.1 <0.001
Triglyceride, mg/dL 102 (73, 146) 130 (94, 181) <0.001 123.9 ± 1.5 163.1 ± 4.9 <0.001 115 (89, 150) 133 (102, 179) <0.001
HDL-cholesterol, mg/dL 57.9 ± 13.5 53.4 ± 11.9 <0.001 48.4 ± 0.2 45.4 ± 0.5 <0.001 46.3 ± 10.0 45.1 ± 9.8 <0.001
LDL-cholesterol, mg/dL 128.9 ± 30.7 135.4 ± 33.2 <0.001 113.2 ± 0.5 118.0 ± 1.7 0.007 114.7 ± 30.4 121.2 ± 31.8 <0.001
AST, IU/L 24 (20, 31) 28 (23, 36) <0.001 21.8 ± 0.2 23.9 ± 0.5 <0.001 25 (22, 29) 26 (23, 30) <0.001
ALT, IU/L 20 (14, 30) 27 (19, 41) <0.001 21.1 ± 0.3 23.7 ± 0.8 0.002 19 (16, 26) 21 (18, 28) <0.001
Current smoker, % 17.7 15.7 0.038 19.9 16.2 0.091 21.4 17.4 0.011
Current drinker, % 64.6 52.4 <0.001 53.2 41.6 <0.001 45.0 39.0 0.002
Regular exercise, % 23.7 28.0 <0.001 23.3 19.0 0.049 52.2 48.7 0.071
Daily caloric intake, kcal/day - - - 1888.6 ± 14.8 1646.1 ± 33.3 <0.001 1851.7 (1546.3, 2200.9) 1772.2 (1460.2, 2137.1) 0.001
Daily protein intake, g/day - - - 68.7 ± 0.7 57.1 ± 1.5 <0.001 62.6 (48.7, 78.0) 57.5 (44.7, 74.6) <0.001
Daily fat intake, g/day - - - 37.7 ± 0.6 27.3 ± 1.3 <0.001 30.0 (14.2, 41.2) 25.8 (17.0, 37.8) <0.001
Daily CHO intake, g/day - - - 311.7 ± 2.3 286.6 ± 5.6 <0.001 323.8 (278.1, 376.3) 315.9 (275.4, 375.6) 0.252
Skeletal muscle index 1.938 ± 0.324 1.530 ± 0.271 <0.001 0.768 ± 0.003 0.581 ± 0.007 <0.001 1.842 ± 0.309 1.519 ± 0.254 <0.001
NAFLD liver fat score - - - −1.381 ± 0.021 −0.9110 ± 0.064 <0.001 −1.958 ± 0.636 −1.747 ± 0.648 <0.001
NAFLD, % 37.1 66.5 <0.001 20.8 34.7 <0.001 - - -
History of CVD, % 4.2 7.8 <0.001 2.7 10.5 <0.001 2.1 3.1 0.081
Abbreviations: SMI, skeletal muscle mass index; LSMI, low skeletal muscle mass index; KNHANES, Korean National Health and Nutrition Examination Survey; KoGES, The Korean Genome and Epidemiology
Study; LSMI, low skeletal muscle mass index; SE, standard error; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; CHO, carbohydrate; NAFLD, non-alcoholic fatty liver disease; CVD, cardiovascular disease. * p derived from Student’s t-test for continuous variables and chi-square test for categorical
variables. † p derived from weighted generalized linear regression analysis for continuous variables and weighted chi-square test for categorical variables.
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Figure 1 presents prevalence of LSMI according to grade of fatty liver examined by
abdominal ultrasonography in the GSHC. Compared to normal (11.8%), prevalence of
LSMI gradually increased with increasing fatty liver grade (p < 0.001).




Figure 1. Prevalence of LSMI according to the grade of fatty liver examined by abdominal ultraso-
nography in the GSHC. Abbreviations: LSMI, low skeletal muscle mass index; GSHC, Gangnam 
Severance Hospital Check-up; NAFLD, non-alcoholic fatty liver disease. 
2.2. Relationship between SMI and NAFLD 
In the first cohort set of the KoGES, the incident LSMI rate per 2 years were ranged 
from 2.0 to 19.9. Moreover, incident NAFLD rate per 2 years were ranged from 4.6 to 10.4 
in the analysis of the second cohort set of the KoGES (Table S1). The cumulative incidence 
of LSMI according to NAFLD status in the KoGES data is presented in Figure S1 as 
Kaplan–Meier curves. NAFLD group had higher cumulative incidence of LSMI over 12 
years with significance (log-rank test, p < 0.001). Figure S2 shows Kaplan–Meier curves for 
cumulative incident NAFLD according to LSMI status. LSMI group showed higher cumu-
lative incidence of NAFLD over 12 years with significance (log-rank test, p < 0.001). 
Figures 2 and 3 show the association between SMI and NAFLD in the three datasets. 
In Figure 2, the hazard ratios (HRs) with 95% confidence intervals (CIs) for incident LSMI 
in the NAFLD group in the KoGES, compared to normal group, was 1.21 (1.05–1.40) after 
adjusting for age, sex, abdominal obesity, physical activity, smoking status, current drink-
ing status, BEE, daily protein intake, MBP, fasting glucose, total cholesterol, and history 
of CVD. In the subgroup analysis, the high energy intake/BEE ratio (EI/BEE) subgroup 
and physically inactive group had significantly higher HRs with 95% CIs for incident 
LSMI of the NAFLD group compared to the normal group (Table S2). The fully adjusted 
HRs (95% CIs) for incident LSMI per 1 standard deviation (SD) increase in NAFLD-liver 
fat score are shown in Table S3. The fully adjusted odds ratios (ORs) (95% CIs) incident 
LSMI in the NAFLD group were 1.78 (1.33–2.38) in the KNHANES and 2.59 (2.26–2.97) in 
the GSHC, respectively, after adjusting all confounding variables, except for daily protein 
intake in the GSHC. 
Figure 1. Prevalence of LSMI according o the grade of fatty liver examined y abdominal ultra-
sonography in the GSHC. Abbreviations: LSMI, low ske etal muscle mass index; GSHC, Gangnam
Severance Hospital Check-up; NAFLD, non-alcoholic fatty liver disease.
2.2. Relationship between SMI and NAFLD
In the first cohort set of the KoGES, the incident LSMI rate per 2 years were ranged
from 2.0 to 19.9. Moreover, incident NAFLD rate per 2 years were ranged from 4.6 to
10.4 in the analysis of the second cohort set of the KoGES (Table S1). The cumulative
incidence of LSMI according to NAFLD status in the KoGES data is presented in Figure S1
as Kaplan–Meier curves. NAFLD group had higher cumulative incidence of LSMI over
12 years with significance (log-rank test, p < 0.001). Figure S2 shows Kaplan–Meier curves
for cumulative incident NAFLD according to LSMI status. LSMI group showed higher
cumulative incidence of NAFLD over 12 years with significance (log-rank test, p < 0.001).
Figures 2 and 3 show the association between SMI and NAFLD in the three datasets.
In Figure 2, the hazard ratios (HRs) with 95% confidence intervals (CIs) for incident LSMI
in the NAFLD group in the KoGES, compared to normal group, was 1.21 (1.05–1.40) after
adjusting for age, sex, abdominal obesity, physical activity, smoking status, current drinking
status, BEE, daily protein intake, MBP, fasting glucose, total cholesterol, and history of
CVD. In the subgroup analysis, the high energy intake/BEE ratio (EI/BEE) subgroup and
physically inactive group had significantly higher HRs with 95% CIs for incident LSMI of
the NAFLD group compared to the normal group (Table S2). The fully adjusted HRs (95%
CIs) for incident LSMI per 1 standard deviation (SD) increase in NAFLD-liver fat score are
shown in Table S3. The fully adjusted odds ratios (ORs) (95% CIs) incident LSMI in the
NAFLD group were 1.78 (1.33–2.38) in the KNHANES and 2.59 (2.26–2.97) in the GSHC,
respectively, after adjusting all confounding variables, except for daily protein intake in
the GSHC.
In Figure 3, the fully adjusted HR (95% CIs) for incident NAFLD in the LSMI group in
the KoGES, compared to normal group, was 1.56 (1.38–1.78). In the subgroup analysis, the
HR with 95% CI for incident NAFLD of LSMI was significantly higher compared to normal
SMI regardless of EI/BEE and physical activity status (Table S4). The fully adjusted HRs
(95% CIs) of incident NAFLD per sex-specific 1 SD increase in SMI are shown in Table S5.
The fully adjusted ORs (95% CIs) for incident NAFLD in LSMI groups were 1.77 (1.35–2.31)
in the KNHANES and 2.34 (2.04–2.68) in the GSHC.
Table 3 shows the independent association among LSMI status with or without ab-
dominal obesity and NAFLD. The fully adjusted HRs (95% CIs) for incident NAFLD in
the LSMI without abdominal obesity group, normal SMI with abdominal obesity group,
and LSMI with abdominal obesity group in the KoGES, compared to normal SMI with-
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out abdominal obesity group, were 1.57 (1.35–1.83), 1.39 (1.18–1.65), and 2.15 (1.79–2.60),
respectively, after adjusting for all confounding variables, except for abdominal obesity.
The fully adjusted ORs (95% CIs) for NAFLD in the LSMI without abdominal obesity
group, normal SMI with abdominal obesity, and LSMI with abdominal obesity, compared
to normal SMI without abdominal obesity group, were 1.67 (1.08–2.56), 1.42 (1.10–1.83), and
2.63 (1.87–3.71) in the KNHANES and 2.76 (2.34–3.27), 3.14 (2.70–3.66), and 5.67 (4.80–6.69)
in the GSHC, respectively.




Figure 2. Forest plot of ORs or HRs with 95% CIs for low skeletal muscle mass index (LSMI) ac-
cording to NAFLD status. Abbreviations: HRs, hazard ratios; ORs, odds ratios; CIs, confidence 
intervals; LSMI, low skeletal muscle mass index; NAFLD, non-alcoholic fatty liver disease; 
KNHANES, Korean National Health and Nutrition Examination Survey; KoGES, Korean Genome 
and Epidemiology Study. 
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2.3. Longitudinal Changes in SMI According to NAFLD
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3. Discussion
In this longitudinal cohort study, we documented a relationship between LSMI and
NAFLD regardless of abdominal obesity. Participants with NAFLD consistently had lower
mean SMI values than those without NAFLD during all follow-up periods. In the subgroup
analysis, the HRs for incident LSMI was significantly higher in the physically inactive
subgroup, which emphasizes the importance of physical activity. On the other hand,
the HRs for incident NAFLD was increased regardless of EI/BEE or physical activity,
which suggests LSMI may be a more important risk factor than diet and exercise in the
development of NAFLD.
In most guidelines, the management of NAFLD has primarily involved efforts to
reduce oxidative stress and to improve insulin resistance, along with weight loss, for the
prevention and treatment of NAFLD [5–7]. Recently, however, emerging studies have
suggested the importance of maintaining and increasing muscle mass for preventing
NAFLD [11–14]. In line with previous studies, we verified that participants who had
LSMI were more likely to have incident NAFLD. Furthermore, we confirmed that both
LSMI with and without abdominal obesity were significantly related with an increased risk
for incident NAFLD. Therefore, maintaining adequate muscle mass could be an effective
strategy through which to reduce the risk of NAFLD independently of abdominal obesity.
Interestingly, although normal SMI with abdominal obesity group showed higher ORs or
HRs with 95% CIs compared to LSMI without abdominal obesity group in the unadjusted
model in all three datasets, the ORs or HRs with 95% CIs were higher in the LSMI without
abdominal obesity group than in the normal SMI with abdominal obesity group in the
fully adjusted model in the KNHANES and KoGES. As there was no consistent result for
each dataset, it was difficult to verify the superiority between muscle mass and abdominal
obesity on the effect of incident NAFLD.
There have been limited studies on the association between NAFLD and incident
LSMI [17–19]. We discovered that participants with NAFLD were more likely to develop
LSMI after adjusting for abdominal obesity and other confounding factors using three
different datasets. In addition, to the best of our knowledge, this is the first study to
consider changes in muscle mass according to the presence of NAFLD. We found that
mean values of SMI were consistently lower in NAFLD patients than in normal individuals
during 12 years of follow-up. Previous studies reported that hepatic disorders may affect
muscle protein homeostasis via insulin resistance, chronic inflammation, and decreased
myokines [17,20]. In this study, however, the difference of SMI between groups gradually
decreased over time, suggesting that the cross-sectional association might be the driving
factor for incident low muscle mass. In addition, because we set SMI as BMI-adjusted TSM
in the KoGES, the gap of SMI between groups could be narrowed over time if BMI-related
factors including exercise, diet, and body composition were more effective than NAFLD
on muscle metabolism. Therefore, it is inconclusive whether NAFLD aggravates muscle
degradation in this study. Further researches should be warranted to verify how much
NAFLD affects the muscle mass.
Although the precise mechanism of the relationship between SMI and NAFLD cannot
be defined by our results, we suggest a possible explanation between muscle and liver
metabolism via hepatokines and myokines. Hepatokines, including leukocyte cell-derived
chemotaxin 2 (LECT2) and hepassocin (HSP), can contribute to the development of LSMI
by increasing insulin resistance [21,22]. In experimental models, LECT2 has been found to
impair insulin signaling pathway through phosphorylation of Jun NH2-terminal kinase
in C2C12 myocyte [21] and HSP has been shown to contribute to the development of
insulin resistance in skeletal muscle via epidermal growth factor receptor/c-Jun N-terminal
kinase (EGFR/JNK)-mediated pathway [22]. Irisin, a myokine that promotes energy
expenditure [23], has also been shown to improve hepatic steatosis by activating AMP-
activated protein kinase and by inhibiting transcription of sterol regulatory element-binding
transcription factor 2 in hepatocytes [24]. Therefore, reduced irisin secretion with a decrease
in muscle mass might affect incident NAFLD.
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Our study has several limitations. First, we could not evaluate various risk factors
associated with fatty liver, such as autoimmune hepatitis, Wilson’s disease, and medica-
tions, due to a lack of information. However, autoimmune hepatitis and Wilson’s disease
are rare diseases, and we excluded viral hepatitis and habitual heavy drinking to minimize
confounding factors between muscle mass and NAFLD, a major cause of chronic liver
disease in Koreans [25]. Second, as we could not use ASM in the GSHC and KoGES due to
the lack of data, we could not apply the commonly used diagnostic criteria for sarcopenia.
To overcome this limitation, we also performed analysis using the KNHANES dataset
with ASM data by applying the Foundation for the National Institutes of Health (FNIH)
Sarcopenia Project criteria. In addition, although the definition of sarcopenia includes not
only muscle mass but also muscle strength and performance, we could not evaluate muscle
strength or performance. Further studies considering muscle strength and performance
should be conducted. Finally, our results would be difficult to apply to other races and
await further validation in more diverse populations.
4. Materials and Methods
4.1. Study Population
This study consists of three different datasets: The KoGES, the 2008–2010 KNHANES,
and the GSHC.
The KoGES is a longitudinal cohort study designed to identify risk factors for non-
communicable diseases [26]. At the baseline survey conducted in 2001–2002, adults aged
40–69 years in urban (Ansan) and rural areas (Ansung) were recruited into the cohort. The
participants were biennially followed up in the study until 2013–2014. The KNHANES is
a nationwide, representative, population-based survey annually conducted by the Korea
Centers for Disease Control and Prevention. Sample weights were assigned to participants
to represent the general Korean population. At the GSHC, adults underwent a medical
examination between 1 October 2016 and 31 January 2017.
The study population selection processes are described in Figure S3. From a total of
10,030 participants in the KoGES baseline survey, we selected a total of 6567 participants
by applying common exclusion criteria: (1) those who had a history of hepatitis (n = 423),
(2) those who consumed ≥30 g/day of alcohol in men and ≥20 g/day in women (n = 964),
(3) those for whom NAFLD liver fat score could not be calculated (n = 276), and (4) those
without bioelectrical impedance analysis (BIA) data (n = 1800). In the first cohort analysis,
we included a total of 4587 participants to analyze incident low skeletal muscle mass index
(LSMI) according to NAFLD status after further excluding those who had LSMI at the
baseline survey (n = 1313) and those who had no follow-up data from the baseline survey
(n = 667). In the second cohort analysis to confirm the relationship between SMI and
incident NAFLD, a total of 4236 participants was finally included after further excluding
those who had NAFLD at baseline survey (n = 1677) and those who had been lost follow-up
thereafter (n = 654).
In the 2008–2010 KNHANES database, from a total of 21,811 adults, we excluded those
who were positive for HBsAg (n = 1341), who were positive for anti-HCV antibody (n = 12),
those who consumed ≥30 g/day of alcohol in men and ≥20 g/day in women (n = 1791),
those for whom NAFLD liver fat score could not be calculated (n = 8390), and those missing
dual energy X-ray absorptiometry (DXA) data (n = 1957). Finally, 8320 individuals were
included in the analysis.
In the GSHC database, from a total of 19,710 adults, we excluded those who were
positive for HBsAg (n = 1208), those who were positive for anti-HCV antibody (n = 951),
those who consumed ≥30 g/day of alcohol in men and ≥20 g/day in women (n = 793),
and those without abdominal ultrasonography data (n = 17) or BIA data (n = 8485). Finally,
a total of 9691 participants was included in the analysis.
Informed consent was obtained from all participants in the KoGES, KNHANES, and
GSHC. This study was approved by the Institutional Review Boards (IRB) of Yongin Sever-
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ance Hospital (IRB number: 9-2020-0043) and Gangnam Severance Hospital (IRB number:
3-2019-0135).
4.2. Assessment of Body Composition
Body weight and height were measured to the nearest 0.1 kg and 0.001 m, respectively.
BMI was calculated as body weight divided by height squared (kg/m2). WC was mea-
sured in the horizontal plane midway between lowest rib and the iliac crest. We defined
abdominal obesity as WC ≥ 90 cm in men and ≥85 cm in women according to Korean
specific cut-offs for abdominal obesity [27].
Participants from the three datasets, respectively, were classified into the LSMI group
or normal group. In the GSHC and KoGES, total skeletal muscle mass (TSM) values were
obtained from a multi-frequency BIA (Inbody 330, Biospace, Seoul, Korea), which has
been used to assess sarcopenia [28,29]. In the 2008–2010 KNHANES, body composition
was assessed by DXA examinations (QDR 4500A; Hologic Inc., Bedford, MA, USA). Body
composition data were collected for the head, trunk, pelvic region, arms, legs, and whole
body. Skeletal muscle mass was calculated as follows: lean body mass (g)—bone mineral
content (g). We calculated appendicular skeletal muscle mass (ASM) using the sum of
skeletal muscle mass values for both the arms and legs.
Combining the height-adjusted and weight-adjusted skeletal muscle indices was
more closely associated with poor physical performance than using either of the indices
alone [30]. Therefore, we defined SMI as TSM (kg)/BMI in the GSHC and KoGES and as
ASM (kg)/BMI in the KNHANES. Finally, LSMI was defined as the sex-specific lowest
quintile of SMI in the GSHC and the KoGES and as a SMI < 0.789 in men and <0.512 in
women according to the FNIH Sarcopenia Project criteria in the KNHANES [31].
In addition, we further analyzed four groups (LSMI without abdominal obesity,
normal SMI with abdominal obesity, LSMI with abdominal obesity, and normal SMI
without abdominal obesity) to investigate the relationship between SMI and NAFLD in
consideration of abdominal obesity.
4.3. Assessment of NAFLD
In the GSHC, NAFLD was diagnosed if fatty liver, focal fat sparing, or fat deposition
was observed on abdominal ultrasonography performed by a well-trained radiologist.
Fatty liver was classified into five categories: mild, mild to moderate, moderate, moderate
to severe, or severe. In the KNHANES and the KoGES, we defined NAFLD using a
validated fatty liver prediction model, NAFLD-liver fat score [32]. The calculation equation
is described in Table S6. Finally, participants in the three datasets were classified into two
groups: NAFLD group and normal group.
4.4. Covariates
In all three datasets, systolic blood pressure (SBP) and diastolic blood pressure (DBP)
were defined as the average of the last two of three measured values. MBP was then
calculated as DBP + 1/3 ∗ (SBP − DBP). Blood tests for measuring serum insulin, total
cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, AST, ALT, and plasma glucose
levels were performed after at least 8 h of fasting using a Hitachi 700-110 Chemistry
Analyzer (Hitachi Co., Tokyo, Japan). Smoking and drinking status were reported via self-
reported questionnaires. We divided smoking status into two categories: current smoking
or not. We also divided alcohol drinking status into two categories: current drinking or not.
The equation used to calculate BEE is described in Table S7 [33]. Participants were classified
into two categories according to the sex-specific median values of EI/BEE (1.23 in men and
1.43 in women, respectively): high EI/BEE group and low EI/BEE group [34]. Participants
who had experienced ischemic stroke, myocardial infarction, or angina pectoris were
considered to have a history of cardiovascular disease (CVD). Physical activity was divided
into two categories: regular exercise and irregular exercise. Regular exercise was defined
as exercising ≥3 times/week in the KoGES and the GSHC, whereas regular exercise was
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defined when a person exercises vigorously ≥20 min at least 3 days/week or ≥30 min of
moderate exercise/walking at least 5 days/week in the KNHANES.
For the KoGES, a validated 103-food item food frequency questionnaire (FFQ) was
used. In the KNHANES, well-trained dietitians conducted in-person interviews with
participants for dietary surveillance using 24-h recall methods. We used daily total calorie
intake (kcal/day), protein intake (g/day), fat intake (g/day), and carbohydrate intake
(g/day) calculated through 24-h recall methods in KNHANES and FFQ in the KoGES,
respectively. In the GSHC, nutritional status was not recorded.
4.5. Statistical Analysis
All data in the KoGES and the GSHC are presented as means ± SD or medians (25th,
75th quartile) for continuous variables and as percentage (%) for categorical variables.
For continuous variables, independent t-tests were used to compare differences between
two groups. For categorical variables, chi-square tests were used to compare differences
between groups. All data in the 2008–2010 KNHANES are presented as mean ± standard
error (SE) for continuous variables and as percentage (%) for categorical variables. For
continuous variables, weighted independent t-tests were used to compare differences
between groups. Weighted chi-square tests were used to compare differences between
groups for categorical variables.
In the KoGES, cumulative incidence of LSMI and NAFLD were represented by Kaplan–
Meier curves. We used log-rank tests to determine if distributions of cumulative incident
LSMI and NAFLD differed between groups. Multivariate Cox proportional hazards re-
gression models were used to calculate HRs with 95% CIs for incident LSMI according
to NAFLD after adjusting for potential confounding variables. Conversely, HRs with
95% CIs for development of NAFLD in the LSMI group in comparison to the normal SMI
group were calculated through multivariate Cox proportional hazards regression models.
Subgroup analyses by EI/BEE and physical activity were performed. We also calculated
HRs with 95% CIs for incident NALFD according to SMI considering abdominal obesity
using multivariate Cox proportional regression models. A linear mixed model for repeated
measures was used to assess the longitudinal relationship between baseline NAFLD status
and subsequent changes in BMI-adjusted total skeletal muscle mass over 12 years of follow-
up after adjusting for baseline confounding factors. In the KNHANES and the GSHC, ORs
and 95% CIs were calculated using a multivariate logistic regression analysis to evaluate
the relationship between SMI and NAFLD.
Statistical analyses were conducted using SAS statistical software (version 9.4; SAS
Institute Inc., Cary, NC, USA) in the KoGES and SPSS statistical software (version 23.0;
SPSS Inc., Chicago, IL, USA) in the GSHC and the KNHANES. The significance level was
set at p < 0.05.
5. Conclusions
LSMI and NAFLD exhibit a relationship regardless of abdominal obesity. Furthermore,
participants with NAFLD consistently had lower muscle mass than those without. Thus,
strategies to preserve muscle mass would be helpful to prevent NAFLD. Furthermore,
lifestyle modification to decrease NAFLD could be helpful to inhibit muscle loss. Experi-
mental studies are needed to identify the underlying mechanism between muscle mass
and hepatic steatosis.
Supplementary Materials: The following are available online at https://www.mdpi.com/2079-773
7/10/2/122/s1, Table S1. Incidence of LSMI during the follow-up study, Table S2. Subgroup analysis
of incident LSMI according to NAFLD status, Table S3, HR and 95% CI for incident LSMI per 1 SD
increase in NAFLD-liver fat score, Table S4. Subgroup analysis of incident NAFLD according to LSMI
status, Table S5. HR and 95% CI for incident NAFLD per 1 SD increase in SMI according to sex, Table
S6. Definitions of previous risk models for NAFLD, Table S7. Equations to calculate basal energy
expenditure (kcal/day), Figure S1. Kaplan-Meier curves for incident LSMI according to NAFLD
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